Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222235 · ClinicalTrials.gov registry record · Phase 2
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT00222235 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 240 participants.
The verdict
NCT00222235, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia.
Interventions
- DRUG placebo
- DRUG d-cycloserine
- DRUG glycine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2000-01 |
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222235
The ClinicalTrials.gov registry entry for NCT00222235 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00222235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222235 about?
NCT00222235 is a clinical study titled "Adjunctive Treatment for Decreasing Symptoms of Schizophrenia". This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia.
What is the current status of trial NCT00222235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2000-01. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00222235?
The interventions under investigation include: placebo (DRUG), d-cycloserine (DRUG), glycine (DRUG).
Who is sponsoring clinical trial NCT00222235?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.